Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario La Fe (21)

2024

  1. Incidence and clinical impact of inappropriate periprocedural and perioperative management of antiplatelet therapy

    Medicina Clinica, Vol. 163, Núm. 7, pp. 336-343

  2. Periprocedural use of antithrombotic therapy in interventional cardiology in Spain: are we doing better than other specialties?

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 701-703

2023

  1. Changes in echocardiographic parameters over time in paradoxical low-flow low-gradient aortic stenosis

    European heart journal. Cardiovascular Imaging, Vol. 24, Núm. 8, pp. 1120-1128

  2. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in “real world”: the REQXAA study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 729-738

2021

  1. Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction

    Journal of the American College of Cardiology, Vol. 78, Núm. 7, pp. 643-662

2018

  1. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU

    Revista Espanola de Cardiologia, Vol. 71, Núm. 7, pp. 553-564

2016

  1. Interhospital Variability in Drug Prescription after Acute Coronary Syndrome: Insights from the ACDC Study

    Revista Espanola de Cardiologia, Vol. 69, Núm. 2, pp. 117-124

2015

  1. Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

    Journal of Internal Medicine, Vol. 278, Núm. 1, pp. 50-58

  2. TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy

    European Journal of Clinical Investigation, Vol. 45, Núm. 2, pp. 179-186

2013

  1. Drug-eluting stents for off-label indications in real clinical world: Evidence based or 'intuition' based clinical practice?

    International Journal of Cardiology, Vol. 164, Núm. 1, pp. 116-122

2011

  1. Reducción de la mortalidad precoz y a 6 meses en pacientes con IAM en el periodo 1995-2005. Datos de los registros PRIAMHO I, II y MASCARA

    Revista Espanola de Cardiologia, Vol. 64, Núm. 11, pp. 972-980

2009

  1. Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 483-486

  2. Insights into the role of microRNAs in cardiac diseases: From biological signalling to therapeutic targets

    Cardiovascular and Hematological Agents in Medicinal Chemistry, Vol. 7, Núm. 1, pp. 82-90

  3. Patient registries of acute coronary syndrome assessing or biasing the clinical real world data?

    Circulation: Cardiovascular Quality and Outcomes, Vol. 2, Núm. 6, pp. 540-547

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

  2. Endothelial protein C receptor polymorphisms and risk of myocardial infarction

    Haematologica, Vol. 93, Núm. 9, pp. 1358-1363

2006

  1. Maximum longitudinal relaxation velocity of the left ventricle: Its clinical value and relationship with NT-proBNP plasma levels in heart failure

    Echocardiography, Vol. 23, Núm. 4, pp. 295-302

  2. Valores de 8-hidroxi-2'-desoxiguanosina y de peroxidación lipídica en pacientes con insuficiencia cardiaca

    Revista Espanola de Cardiologia, Vol. 59, Núm. 11, pp. 1140-1145

2005

  1. Relación de los valores plasmáticos de big endotelina-1 con Nt-proBNP y la función ventricular de pacientes con insuficiencia cardíaca

    Revista Espanola de Cardiologia, Vol. 58, Núm. 3, pp. 278-284

2004

  1. Hipertensión y valores de NT-proBNP. Su importacia en el diagnóstico de insuficiencia cardíaca

    Revista Espanola de Cardiologia, Vol. 57, Núm. 5, pp. 396-402